» Articles » PMID: 21941653

Primary Molecular Disorders and Secondary Biological Adaptations in Bartter Syndrome

Overview
Journal Int J Nephrol
Publisher Wiley
Specialty Nephrology
Date 2011 Sep 24
PMID 21941653
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Bartter syndrome is a hereditary disorder that has been characterized by the association of hypokalemia, alkalosis, and the hypertrophy of the juxtaglomerular complex with secondary hyperaldosteronism and normal blood pressure. By contrast, the genetic causes of Bartter syndrome primarily affect molecular structures directly involved in the sodium reabsorption at the level of the Henle loop. The ensuing urinary sodium wasting and chronic sodium depletion are responsible for the contraction of the extracellular volume, the activation of the renin-aldosterone axis, the secretion of prostaglandins, and the biological adaptations of downstream tubular segments, meaning the distal convoluted tubule and the collecting duct. These secondary biological adaptations lead to hypokalemia and alkalosis, illustrating a close integration of the solutes regulation in the tubular structures.

Citing Articles

A Case of a Novel MAGED2 Mutation Resulting in Non-transient Bartter's Syndrome in an Adult Female.

Albaba I, Azher S, Mehta S, Faddoul G Cureus. 2023; 15(5):e38681.

PMID: 37288186 PMC: 10243719. DOI: 10.7759/cureus.38681.


A highly unusual case of osmotic demyelination syndrome and extrapontine myelinolysis in a 3-month-old infant with Bartter syndrome.

Gargano G, Manfredi M, Pedori S, Di Dio F, Spagnoli C, Frattini D J Int Med Res. 2020; 48(10):300060520966494.

PMID: 33107776 PMC: 7645388. DOI: 10.1177/0300060520966494.


Bartter syndrome: causes, diagnosis, and treatment.

Cunha T, Heilberg I Int J Nephrol Renovasc Dis. 2018; 11:291-301.

PMID: 30519073 PMC: 6233707. DOI: 10.2147/IJNRD.S155397.


Unusual Complication of Multidrug Resistant Tuberculosis.

Sharma P, Sahay R Case Rep Nephrol. 2017; 2017:6835813.

PMID: 29075541 PMC: 5624136. DOI: 10.1155/2017/6835813.


Increased urinary prostaglandin E2 metabolite: A potential therapeutic target of Gitelman syndrome.

Peng X, Jiang L, Chen C, Qin Y, Yuan T, Wang O PLoS One. 2017; 12(7):e0180811.

PMID: 28700713 PMC: 5507263. DOI: 10.1371/journal.pone.0180811.


References
1.
Bartter F, PRONOVE P, GILL Jr J, MacCARDLE R . Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. 1962. J Am Soc Nephrol. 1998; 9(3):516-28. DOI: 10.1681/ASN.V93516. View

2.
Crinnion W, Tran J . Case report: heavy metal burden presenting as Bartter syndrome. Altern Med Rev. 2011; 15(4):303-10. View

3.
Kleta R, Basoglu C, Kuwertz-Broking E . New treatment options for Bartter's syndrome. N Engl J Med. 2000; 343(9):661-2. DOI: 10.1056/NEJM200008313430915. View

4.
Pressler C, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S . Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am Soc Nephrol. 2006; 17(8):2136-42. DOI: 10.1681/ASN.2005101071. View

5.
Vargas-Poussou R, Huang C, Hulin P, Houillier P, Jeunemaitre X, Paillard M . Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol. 2002; 13(9):2259-66. DOI: 10.1097/01.asn.0000025781.16723.68. View